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produce improved immunogenicity in patients
with cancerMayu O Frank1†, Julia Kaufman1†, Salina Parveen1, Nathalie E Blachère1,2, Dana E Orange1,4 and Robert B Darnell1,2,3*Abstract
Background: Dendritic cells are currently under investigation for their ability to generate anti-cancer immune
responses. No consensus has been reached as to the optimal method of dendritic cell vaccine preparation and is a
barrier to success in the field.
Methods: Over a course of three separate dendritic cell vaccine studies to treat cancer, we tested two different
methods for preparing dendritic cells from peripheral blood mononuclear cells: adherence and antibody-selected
CD14+ cells.
Results: Surprisingly, we found that patients who received dendritic cell vaccines generated by the adherence
method mounted increased T cell proliferation in response to vaccination. This difference could not be accounted
for by dendritic cell vaccine dose, cell surface phenotype or dendritic cell function in vitro. One notable difference
between the two vaccine preparation methods was that the dendritic cell vaccine cultures generated by the
adherence method contained up to 10% lymphocytes, and these lymphocytes were proliferating and producing
IFNγ in response to antigen in vitro at the time of administration.
Conclusions: Enhanced immunogenicity of adherence dendritic cell vaccinations may be due to the presence of
lymphocytes during dendritic cell culture.
Trial registration: Clinicaltrials.gov identifiers: NCT00289341, NCT00345293, and NCT00893945
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Dendritic cells (DCs) are potent antigen presenting cells
(APCs), which prime and activate CD4 helper [1] and
CD8 cytotoxic killer T cells [2] and are therefore useful
for initiating cancer specific immune responses. In fact,
at the time of this writing, there are 417 studies listed on
clinicaltrials.gov retrieved with the search terms, “dendritic
cell” and “cancer”. Despite 20 years of DC vaccine trials,
clinically meaningful responses have been sparse. In the
search for more potent DC vaccines, different methods of* Correspondence: darnelr@rockefeller.edu
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unless otherwise stated.precursor isolation, cell differentiation, antigen pulsing,
maturation and the use of adjuvants are being evaluated.
While the use of peripherally circulating monocytes as
precursors and IL-4 and GM-CSF for differentiation have
become an accepted standard [3,4], other areas of DC vac-
cine production remain highly variable [3,5].
In our own studies, we have explored the use of apop-
totic tumor cells as a source of antigen for DCs. This
concept arose from the finding that patients with para-
neoplastic neurologic disorders (PND) can exhibit po-
tent, naturally occurring tumor immunity and harbor
antigen specific T cells to neuronal antigens [6]. At the
same time, while DCs are required to initiate de novo T
cell responses, the source of antigen for the DCs was un-
known, as DCs do not express the neuronal PND anti-
gens. These observations, together with those of Rosentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the packaging of Lupus auto antigens into membrane-
bound bodies [7], led us to the hypothesis that PND anti-
gens were transferred from apoptotic tumor cells to the
phagocytic DCs, and then presented to naïve T cells to
trigger a potent immune response [8]. This hypothesis
was borne out with a model antigen (influenza) and with
PND antigen (cdr2) [6] establishing a basis for the
phenomenon of cross-priming proposed by Bevan [9,10].
Here we tested the immunogenicity of DCs presenting
apoptotic tumor cells in patients with cancer, using 2
different methods of isolating DC precursors: adherence
of peripheral blood mononuclear cells (PBMCs) to plastic
(Adherence DCs) and selection of CD14+ cells using
antibody-conjugated beads by CliniMACS (Selected DCs).
In all studies, vaccines were prepared by culturing DC
precursor cells with IL-4 and GM-CSF for 6 days, after
which immature DCs (iDCs) were cultured with apoptotic
tumor cells and treated with maturation stimulus cocktail
of TNF-α, prostaglandin E2, plus or minus CD40L. Our
first clinical trial of a DC vaccine treatment for prostate
cancer included 24 patients who were treated with Adher-
ence DCs pulsed with apoptotic LNCaP, a prostate cancer
cell line [11]. Proliferation responses were assessed by 3H
thymidine incorporation assay pre- and post-vaccination
and responses to the prostate cell lines LNCaP and PC3
were determined. Treatment induced a statistically signifi-
cant increase in T cell proliferative responses to both pros-
tate tumor cell in vitro.
In a second follow up trial, in an effort to make a more
potent vaccine, two modifications were made to the vac-
cine. First, DCs were made using the selection method,
assuming that there may be benefits to using a purer
vaccine and second, a different prostate cancer cell line,
PC3, was used to pulse the DCs. In our first study in
which patients were vaccinated with DC/LNCaP, post-
vaccination proliferation responses to PC3 (to which pa-
tients were not vaccinated) were equivalent to LNCaP.
Though this was unexpected because the PC3 cells do
not express known prostate cancer antigens such as PSA
and PSMA, this result led us to hypothesize that PC3 is
a more immunogenic cell line. Therefore, in a follow up
study, seven patients were enrolled and vaccinated with
Selected DCs pulsed with apoptotic PC3. Surprisingly, as
we shall describe, the lymphocyte proliferation responses
post-vaccination were markedly lower than that had
been previously observed in the first study. This differ-
ence could not be explained by the amount of vaccine
administered or the maturation status of the DCs. How-
ever, it was not clear whether this observation was due
to the change in prostate cancer cell line used (LNCaP
versus PC3) or the change in the method of DC prepar-
ation (Adherence versus Selected). To test this, we en-
rolled 3 subsequent patients who were given AdherenceDC pulsed with PC3 to assess whether the change in the
method of DC preparation was the cause of the differ-
ence in proliferation. Here, we compare in vitro pheno-
typic and functional similarities and differences between
the two vaccine preparation methods.
Methods
Patients and study design
Two separate DC vaccination studies were conducted
for prostate cancer patients, the first using apoptotic
LNCaP cells, as reported previously [11], and the second
using apoptotic PC3 cells. Patients in the first study were
vaccinated with DCs pulsed with LNCaP (DC/LNCaP)
and DCs pulsed with LNCaP transfected with influenza
M1 protein (DC/LNCaP-M1) [11]. In the second study pa-
tients were vaccinated with DCs pulsed with PC3 (DC/
PC3) and DCs pulsed with PC3 transfected with influenza
M1 (DC/PC3-M1). The ratio of DCs to apoptotic LNCaP
or PC3 tumor cells was 1:1. In both studies, the acceptable
dose range was 1-106 DCs of each type at each time point,
regardless of the method of DC preparation. Patients in
both studies were also given DCs pulsed with KLH (DC/
KLH) as a control antigen. Initial vaccination was followed
by 3 booster vaccine immunizations, each 2 weeks apart,
administered subcutaneously. In both studies, leukocytes
for immunomonitoring were collected by leukapheresis at
baseline and again 6 weeks after the last booster.
In a third study, patients with primary brain tumors
were vaccinated with DCs pulsed with autologous apop-
totic tumor cells and DC/KLH. In this study, both the
number of boosters and the timing of the post-
vaccination leukapheresis were different from the first 2
studies. Patients were vaccinated with either 2 or 3 doses
every 3 weeks intradermally and leukapheresed 2 to 3
weeks after the 2nd dose. Here, we report only the patients’
responses to DC/KLH as relevant and not the responses to
the DC vaccine to brain tumor. In all 3 studies, the first
dose of DC administered was “fresh” and all subsequent
booster doses were thawed doses. All studies were con-
ducted at Rockefeller University Hospital after Institutional
Review Board approval. Written consent was obtained
from all patients. Study identifiers on clinicaltrials.gov
were: NCT00289341, NCT00345293, and NCT00893945.
Adherence method of dendritic cell vaccine preparation
(Adherence DCs)
DCs were prepared as previously described [11]. Briefly,
leukapheresates were placed over lymphocyte separation
media and the buffy layer was collected and washed.
PBMCs were then plated in RPMI-1640 supplemented
with 1% autologous plasma and allowed to adhere at 37°C.
After 1 hour, the non-adherent cells were removed. The
adherent cells were differentiated in RPMI-1640 supple-
mented with 1% autologous plasma, GM-CSF (Genzyme)
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are non-adherent and considered immature DCs. LNCaP
and PC3 cells were obtained directly from American Type
Cell Culture (CRL-1740 and CRL-1435) and cell banks
were established as described [11]. LNCaP or PC3 cells
were UV irradiated and cultured with immature DCs at a
1:1 ratio with PGE2 (Sigma) and TNFα (R & D Systems,
Miltenyi) over 36-48 hours. A subset of immature DCs
was cultured with KLH (biosyn). The cells were harvested
on the 8th day, washed and resuspended in 5% dimethyl
sulfoxide and 10% human serum albumin (HSA, Grifols)
in normal saline for freezing or administration.Selection method of dendritic cell vaccine preparation
(Selected DCs)
Leukapheresates were washed with PBS/EDTA supple-
mented with 2% HSA, incubated with CD14 MicroBeads
(Miltenyi Biotec) for 15 minutes then washed. CD14+
cells were isolated using the CliniMACS System (Milte-
nyi Biotec). Positively selected cells were washed and
plated in RPMI-1640 supplemented with 1% autologous
plasma, GM-CSF (Genzyme) and IL-4 (R & D Systems)
over 6 days. Cells were pulsed with tumor cells, matured
and harvested in the same manner as Adherence DCs.Lymphocyte proliferation assay
Lymphocyte proliferation responses, pre- and post-
vaccination, were measured by 3H-thymidine incorporation
assays as previously described [12] with the following
changes. APCs were either pre-vaccination CD14+ cells or
DCs. 3H-thymidine was added for the last 20 hours of cul-
ture. Results are presented as average count per minute
(CPM) of 3 to 6 replicate wells.Phenotyping by flow cytometry
As part of release criteria testing, DCs were counted and
stained with HLA-DR, CD14, CD83 antibody (Becton
Dickinson) and propidium iodide (Serologicals). For add-
itional phenotyping, cells were stained with CD86, CD40,
CCR7, CD4, CD8, CD69, and CD19 antibody (Becton
Dickinson). Data was acquired on the FACSCalibur
(Becton Dickinson) or MACSQuant VYB (Miltenyi Biotec)
and data were analyzed using FlowJo software.Phagocytosis assay
Immature Selected or Adherence DCs were stained with
HLA-DR-APC and cultured with apoptotic PKH26 stained
allogeneic lymphocytes with or without EDTA for 24
hours. Analysis was restricted to HLA-DR+ cells and the
phagocytosis of apoptotic cells by DC groups were identi-
fied by positive PKH26 dye staining.Allogeneic mixed leukocyte reaction (Allo-MLR)
As previously described [12], DCs were cultured with
the non-adherent fraction of allogeneic PBMCs.
Cytokine analysis
Supernatants of Adherence and Selected DCs were
assessed for the presence of cytokines using the Meso
Scale Discovery Human ProInflammatory 9-Plex plate and
read on the SECTOR Imager (Meso Scale Discovery).
DCs were prepared using each of the 2 methods from 3
donors.
IFNγ ELISPOT
The IFNγ ELISPOTassay was done as previously described
[12] with the following modifications. Influenza-infected
DCs (DCF) were used to elicit influenza-specific IFNγ re-
sponses. Adherence DC vaccine preparations were har-
vested on day 8 and re-plated on an IFNγ ELISPOT coated
plate at a density of 25,000 lymphocytes/well.
Dextramer staining and intracellular flow cytometry
analysis
PBMCs or Adherence DC preparations from A0201 do-
nors were co-cultured with apoptotic 3T3 (DC/ctrl) or
apoptotic influenza-infected 3T3 cells (DC/flu) for 5 hours
in GolgiStop (BD Bioscience) before staining with APC-
conjugated A0201 Influenza-M1 dextramer (GILGFVFTL,
Immudex) followed by CD8-FITC (BD Bioscience). Cells
were fixed and permeabilized (Cytofix/Cytoperm, BD
Bioscience) as per manufacturer’s protocol. Intracellular
cytokine staining was performed using IFNγ − PE (BD
Bioscience) followed by flow cytometry analysis.
Statistical analysis
To evaluate the difference between proliferation re-
sponses between the patients given Selected DCs and
Adherence DCs, the Mann-Whitney test was used. This
test was also used to describe differences in the number
and phenotype of the 2 types of DCs given. The paired
t-test was used to describe differences in all other assays.
P-values less than 0.05 were considered statistically
significant.
Results
Adherence DCs elicit increased proliferation of
lymphocytes post-vaccination
Seven patients received Selected DCs and three received
Adherence DC vaccine preparations, all pulsed with
apoptotic PC3 cells. We compared the post- minus pre-
vaccination proliferation responses of these patients.
There was a significantly higher proliferation response
to PC3 in patients that received Adherence DCs as
compared to those who received Selected DCs (Figure 1A,






















































































































Figure 1 Adherence DCs elicit increased proliferation of lymphocytes post-vaccination. (A) 3H thymidine proliferation responses to prostate
cancer cells lines, PC3, LNCaP or no antigen of lymphocytes from patients vaccinated with either Selected or Adherence DCs pulsed with PC3. CD14+
monocytes were used as APCs. Results are presented as average pre-vaccination counts per minute (CPM) subtracted from average post-vaccination
CPM for each antigen group. The results are the average of 3 to 6 replicate wells. Black line indicates median. * indicates p < 0.05. NS = not statistically
significant. (B) Pooled 3H thymidine proliferation responses to KLH or no antigen of lymphocytes from patients vaccinated with either Selected or
Adherence DCs from 3 clinical trials. ● indicates response of patient in DC/LNCaP study,▲ indicates response of patient in DC/PC3 study, and ■ indicates
response of patient in DC pulsed with autologous brain tumor study.
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ence versus the Selected DC vaccines to LNCaP, another
prostate cancer cell line with which this cohort was not
vaccinated (p = 0.033). Background post-vaccination pro-
liferation responses to APCs not pulsed with antigen did
not differ between the patients receiving Adherence or Se-
lected DC/PC3 vaccines (No Ag, p = 0.867). This data in-
dicated that the DC/PC3 vaccines prepared by Adherence
method elicited higher antigen specific immune responses
than those prepared by the Selection method.
This observed difference in immunogenicity was not
anticipated. Therefore, we confirmed this by pooling
data from other DC vaccine trials conducted by our la-
boratory, including the previously reported study in
prostate cancer patients using DC/LNCaP and an add-
itional DC vaccine study of patients with primary brain
tumors. Since the tumor type was different between
these studies, tumor specific responses could not be rea-
sonably compared. However, all patients were vaccinated
with DC/KLH made with either Selected or Adherence
DCs, therefore, proliferation responses to KLH wereexamined. There were a total of 10 evaluable patients
who received Selected DC/KLH and 31 patients who re-
ceived Adherence DC/KLH. The vaccination induced
significantly higher lymphocyte proliferation responses
to KLH in patients that received Adherence DCs than
those that received Selected DCs (Figure 1B; p = 0.023).
No difference was observed in the proliferative lympho-
cyte responses to negative control APCs (not pulsed
with antigen, p = 0.576). This result indicates that Adher-
ence DCs consistently elicit higher immunogenicity even
in different populations of cancer patients.
The differences in immunogenicity were not a result
of differences in DC dose, phenotype, such as CD83 or
CD14 expression or a result of differences in DC viabil-
ity. The total number of DC/PC3, DC/PC3-M1, and
DC/KLH administered also did not differ between Ad-
herence and Selected vaccine preparations (Table 1).
Within the second study of DC loaded with apoptotic PC3,
the number of cells administered, the cell surface expres-
sion of CD83 and CD14, and viability of DC/PC3 and DC/
PC3-M1 were similar. Further, in all three studies (DC/
Table 1 Number and phenotype of DCs administered
Median number of DCs administered per patient
no. x 106 (range)
DC/PC3 Selected 28.15 (23.17-37.10)
Adherence 30.73 (25.90-31.84)
p-value >0.99
DC/PC3-M1 Selected 28.86 (20.49-33.85)
Adherence 26.75 (24.80-34.05)
p-value 0.80
Phenotype of DCs administered (median)
CD14+ (%) (range) CD83+ (%) (range) PI+ (%) (range)
DC/PC3 Selected 2.76 (1.85-5.71) 96.18 (86.35-98.46) 7.94 (4.36-18.06)
Adherence 1.09 (0.82-4.41) 97.70 (90.70-98.40) 8.99 (4.81-11.50)
p-value 0.23 >.99 0.87
DC/PC3-M1 Selected 3.45 (1.15-7.9) 95.60 (85.67-98.49) 12.52 (4.34-17.09)
Adherence 2.04 (1.29-6.4) 98.20 (96.80-98.90) 10.10 (5.83-12.60)
p-value 0.87 0.12 0.72
Median number of DC/KLH administered per patient in all three studies




Phenotype of DC/KLH administered in all three studies (median)
CD14+ (%) (range) CD83+ (%) (range) PI+ (%) (range)
Selected 0.64 (0.01-2.00) 96.79 (92.35-99.30) 1.85 (0.92-9.30)
Adherence 0.36 (0-2.82) 95.69 (86.00-99.97) 1.27 (0.34-12.19)
p-value 0.24 0.55 0.10
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same parameters are also similar in the DC/KLH that
were administered. Given such similarities between Ad-
herence and Selected DCs, DC phenotype, viability, and
dose do not explain the difference in immunogenicity.
In vitro assays of DC phenotype and function do not
predict differences in immunogenicity
To test whether Adherence or Selected DCs express dif-
ferent levels of markers of maturation, DCs were prepared
using both methods from the same donor’s PBMC. Adher-
ence and Selected DCs were assessed for the surface
markers CD14, HLA-DR, CD83, CD86, CD40 and CCR7,
but no differences were found (Figure 2A). We next evalu-
ated the in vitro function of the two types of DCs. First,
we assessed their ability to phagocytose apoptotic cells,
which could affect antigen presentation. Selected or
Adherence immature iDCs were cultured with PKH26
stained apoptotic lymphocytes. Cells positive for both
HLA-DR staining and PKH26 dye indicated DC phago-
cytosis of apoptotic cells. 66.4% of Selected and 67% ofAdherence iDCs phagocytosed apoptotic cells, indicating
no difference in their phagocytic activity (Figure 2B). This
process was calcium dependent and inhibited in the pres-
ence of EDTA, indicating that apoptotic cells were phago-
cytosed and not positive for both markers simply by
adhering to one another or other non-specific mechanisms.
We next assayed the functional ability of both DC
types in an allo-MLR assay. Allogeneic lymphocytes
were cultured with Adherence or Selected DCs prepared
from PBMC of the same donor. The proliferative re-
sponse of allogeneic lymphocytes to Adherence DC
was not different than their response to Selected DC
(Figure 2C, p = 0.483). We then tested the ability of the
DC groups to stimulate lymphocyte proliferation in an
antigen specific manner. Selected or Adherence DCs
were co-cultured with either apoptotic 3T3 cells in-
fected with influenza (DC/flu) or uninfected apoptotic
3T3 cells (DC/ctrl). DC/flu or DC/ctrl were then cultured
with syngeneic lymphocytes. Both the Selected and Adher-
ence DCs strongly stimulated influenza-specific lymphocyte











































































































Figure 2 (See legend on next page.)
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Figure 2 In vitro assays of phenotype and function do not predict differences in immunogenicity. (A) Cell surface marker staining. Selected or
Adherence DCs made from the same donor were stained with CD14, CD83, HLA-DR, CD86, CD40 and CCR7 antibody. This is representative of 3
repeated experiments. (B) Phagocytosis assay. HLA-DR stained Selected or Adherence iDCs were cultured with PKH26 stained apoptotic lymphocytes
with or without EDTA for 24 hours. Cells are gated on HLA-DR. Cells staining positive for both HLA-DR and PKH26 indicate phagocytosis of apoptotic
cells by DC groups. The data shown is representative of 3 repeated experiments. (C) Allo-MLR. Selected and Adherence DCs were made from
cells from 3 donors. Average CPMs are shown for syngeneic and allogeneic responses at the DC:T cell ratio of 1:30. Solid black line represents
the mean. NS = not statistically significant. (D) Lymphocyte proliferation. Adherence or Selected DCs co-cultured with apoptotic 3T3 cells
(DC/ctrl) or with influenza-infected 3T3 cells (DC/flu), were cultured with syngeneic CD14- cells. The cultures were assessed for proliferation by
3H thymidine incorporation and the data shown is representative of 3 repeated experiments. NS = not statistically significant. (E) IFNγ ELISPOT.
Purified syngeneic CD8 or CD4 T cells were plated in an ELISPOT with either non-infected DCs (DC) or influenza-infected (DCF) made by the 2
methods. The data shown is an average of triplicate wells and representative of 3 repeated experiments. NS = not statistically significant.
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we assessed the differences in DC ability to induce an IFNγ
response in T cells in an antigen specific manner. DC (DC)
or influenza infected DC (DCF) were co-cultured with ei-
ther CD4 or CD8 T cells in an ELISPOT assay. Again, both
groups of DCs were able to induce a comparable CD4 and
CD8 T cell IFNγ response to influenza (Figure 2E, p = 0.250
and p = 0.822 respectively). In summary, these assays indi-
cate that there is no detectable difference in DC number,
phenotype or function that could account for the observa-
tion that Adherence DCs produced increased immunogen-
icity in patients with cancer.
Lymphocytes in Adherence DC vaccine preparations are
activated and proliferating
We next looked beyond the DCs for an explanation for
why the two vaccine preparations differed in their ability
to stimulate T cell proliferation. Upon examination of
the 10 most recent Adherence and Selected DC vaccines
administered, we found that Adherence DC vaccines
contained a median of 10.8% lymphocytes (range 4.7 to
25.0%, Figure 3A and data not shown), determined by
forward and side scatter on flow cytometry. In contrast,
the Selected DC vaccines contained very few lympho-
cytes (median 1.0%, range 0.3 to 1.8%). Thus, we turned
our attention to assessment of this population of admin-
istered cells. The lymphocytes in the Adherence DC
preparation contained a mixture of CD4, CD8 and CD19
cells (Figure 3A). These lymphocyte populations were
resting at the time of initial harvest from patients’ blood
(Day 0), but were highly activated after 8 days of culture
within the DC vaccine preparation. Both CD4 and CD8
T cells up-regulated CD69 and HLA-DR expression and
CD19 B cells up-regulated CD40, HLA-DR, and CD83
expression compared to baseline PBMC expression at
Day 0 (Figure 3B).
To assess lymphocyte proliferation within the DC
preparations, both Adherence and Selected DCs were
pulsed with 3H-thymidine. Adherence DC preparations
were found to have incorporated more 3H-thymidine
than Selected DCs, an indication that the lymphocytes
were proliferating in these cultures (Figure 4A, p = 0.03,p = 0.003, and p = 0.021 respectively at 48, 72, and 96
hours). In addition, when we examined the Adherence
and Selected DC cultures for the presence of cytokines
after 6 days in culture, we found that the Adherence DC
supernatants contained a mean of 4.42 pg/ml IL-2 while
the levels in the Selected DC culture supernatants were
below the level of detection (<0.68 pg/ml), a statistically
significantly increase (Figure 4B, p = 0.012). This sup-
ports the observation that lymphocytes present in the
Adherence DC culture were proliferating. There was a
similar trend after 2 more days of culture in fresh
media but this difference was not statistically significant
(p = 0.070). There were no differences in the concentra-
tions of IL-8, IL-12p70, IL-1β, IFNγ, IL-6, and IL-10
found in the supernatants of Adherence or Selected DC
cultures. In conclusion, Adherence DC vaccines contain
both DCs as well as CD4+, CD8+ and CD19+ lympho-
cytes that are activated in vitro, are proliferating, and
are producing IL-2.
DC vaccines prepared by adherence support antigen
specific lymphocyte proliferation and activation
Since patient vaccines were prepared by culture of im-
mature (Day 6) DCs with apoptotic tumor cells, we hy-
pothesized that the activated lymphocytes in Adherence
DC cultures may expand in an antigen specific manner
to apoptotic tumor cells. In this scenario, Adherence DC
vaccines could contain an expanded population of tumor
cell-specific, activated lymphocytes in addition to DC
loaded with tumor cell antigen. Since we did not have
enough cancer patient derived specimens to test this dir-
ectly, we tested the more general hypothesis that lympho-
cytes contained in Adherence DC preparations proliferate
in an antigen specific manner to antigens added to DC
cultures on Day 6.
Adherence DCs from healthy donors were co-cultured
with either apoptotic influenza infected cell lines (DC/
flu) or uninfected control cells (DC/ctrl) and tested for
proliferation. There was increased proliferation
(Figure 5A, p = 0.009 at 96 hours) in Adherence DC/flu
cultures compared to Adherence DC/ctrl cultures.
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Figure 3 Lymphocytes in Adherence DC vaccine preparations are activated and proliferating. (A) Representative flow cytometry profile of
forward scatter versus side scatter of Adherence and Selected DC vaccine preparations. CD4, CD8, and CD19 antibody staining of cells in the
lymphocytes gate in the Adherence DC plot is shown by histogram. (B) DCs made with the Adherence method were stained with antibodies to
lymphocyte markers, CD4, CD8 or CD19 and activation markers CD40, CD83, CD69 and HLA-DR and analyzed by flow cytometry. The results shown are
representative of 3 different donors.


























































Figure 4 DC vaccines prepared by Adherence support lymphocyte proliferation and cytokine production. (A) DCs made by the 2
methods were assessed for proliferation by 3H thymidine incorporation at 48, 72, and 96 hours beyond day 8, (the day DCs would have been
administered as vaccine). Proliferation responses for Adherence DCs are shown in red and Selected DCs are shown in purple. The results are averages
of triplicate wells. * indicates p < 0.05. (B) Supernatants of Adherence and Selected DC cultures were examined for pro-inflammatory cytokines on Day
6 and Day 8. Data for IL-2 is shown for 3 donors. Black line represents the mean. * indicates p < 0.05. NS = not statistically significant.
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be critical for the generation of tumor immunity, we
evaluated the cultures for expansion of influenza M1
specific dextramer positive cells. On day 10 of Adher-
ence DC/flu culture, we found an increase in the per-
centage of influenza M1+ CD8+ cells (0.16%)
compared to DC/ctrl cultures (0.0623%) and baseline
PBMCs (0.047%, Figure 5B, upper panels). In addition
to an increase in the frequency of antigen specific cells,
we also found evidence of their activation; on day 10,
75% of the M1-specific CD8 T cells within the DC/flu
culture produced IFNγ (Figure 5B, lower panels). Simi-
lar results were obtained when this experiment was re-
peated with a second donor (52% of M1-specific CD8+
T cells produced IFNγ on day 10). Earlier, when we
assayed the supernatant for cytokines after 6 and 8
days of culture, no IFNγ was detected due to the lack
of antigen. However, when DCs are co-cultured with
antigen such as influenza as it was in this culture, notonly are we able to detect antigen specific proliferation
but we are now able to detect IFNγ within that subset. In
conclusion, Adherence DC cultures contain a population
of proliferating, activated lymphocytes not present in Se-
lected DC cultures and these can expand in an antigen
specific manner.
Discussion
The discovery reported here that a common current
method of preparing DCs for clinical vaccine, based on a
CD14 selection strategy designed to produce purer pop-
ulations of DCs, produced antigen-specific T cells with
reduced proliferative capacity, was entirely unexpected.
A priori, it was hypothesized that purer populations of
DCs would be a more robust vaccine strategy. Exploring
the mechanism for this difference revealed that DCs pre-
pared by the two methods were comparable in their
phenotype and function. We found that the primary dif-







































Figure 5 Proliferation and cytokine production in DC vaccine prepared by adherence method is antigen specific. (A) Adherence DCs
were co-cultured with apoptotic 3T3 (DC/ctrl) or with 3T3 infected with influenza (DC/flu) and assessed for proliferation by 3H thymidine incorporation
at 24, 48 and 96 hours beyond day 8 (the day DCs would have been administered as a vaccine). Results are of triplicate wells. * indicates p < 0.05.
(B) Adherence DC/ctrl and DC/flu were stained with CD8 antibody, influenza-M1 specific dextramer and IFNγ antibody. The original PBMC population
was used as the comparison group. The upper panels shows CD8+ cells that are gated on M1+ staining. The lower panels show M1+ cells that are
gated on IFNγ + cells.
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pure” Adherence vaccine preparations; interestingly, we
found that not only did these lymphocytes survive in the
DC culture but also took on an activated and proliferat-
ing phenotype.
One hypothesis is that these activated and proliferating
lymphocytes were interacting directly with the DCs to
confer Adherence DCs greater potency in vivo compared
to Selected DCs. For example, it has been shown that
survival of DCs can be increased through the TRANCE/TRANCE receptor interaction between a T cell and DC
by up-regulation of Bcl-XL expression in the DC [13]. It
is possible that the presence of activated T cells in the
Adherence DC cultures promoted their survival in vivo
leading to prolonged antigen-presentation and the in-
creased post-vaccination proliferation we observed in our
studies (Figure 1). Further, Berk, et al. showed that iDCs
matured with expanding and activated lymphocytes in-
duced greater IL-12p70 and CXCL10 compared to those
matured with the conventional cytokine cocktail including
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grown with a small number of expanding and activated
lymphocytes, these lymphocytes could have a similar en-
hancing effect on the DCs that potentially contributed to
the boosted immunogenicity post-vaccination.
Adherence DC vaccines also contain many CD19+
CD83+ B cells. CD83 is an early activation marker for B
cells induced by interaction with activated T cells through
CD40 ligation [15,16]. Activated CD83+ B cells are cap-
able of effective tumor-antigen presentation via MHC II
[15] and it is possible that B cells in the Adherence DC
vaccine potentiate immunogenicity. Moreover, some sub-
set of the immune cells activated by Adherence DCs
in vitro, including T cells and B cells, might reasonably be
expected to be tumor antigen specific, a potentially clinic-
ally important observation.
The site of DC administration may be acting as a
nidus for in vivo lymphocyte recruitment. It has been
described that the great majority of DCs administered
do not migrate to the draining lymph node but remain
at the site of injection [17]. Further, it has been shown
that DC/CD4 T cell interactions create local MIP-1α and
MIP-1β gradients that attract naïve CD8 T cells to
lymph nodes [18]. In the work presented here, we find
that lymphocytes in Adherence DC cultures expand and
become activated. It is possible that tumor vaccines that
contain both DCs and ex-vivo activated lymphocytes
could incite local inflammation, recruiting additional
lymphocytes in vivo through such a chemokine gradient
even without trafficking to the lymph node.
There are a number of limitations to this work. First,
we did not explore what components of the lymphocytes
present in the vaccine are necessary for the increased
proliferation seen in patients ex vivo. Further investiga-
tion with additional patients with prostate cancer given
different iterations of the vaccine preparation, such as
one that contains DCs and CD3+ cells but no CD19+
cells and another that contain DCs with CD19+ cells but
no CD3+ cells, for example, are necessary to address this
issue. Secondly, we only show head to head comparison
made between antigen-specific Adherence and Selected
DCs pulsed with apoptotic PC3 cells. It is possible that
this difference in immunogenicity is only present under
these conditions. We did not explore in detail whether
similar differences would be present under other condi-
tions such as with use of alternative sources of antigen,
maturation cocktails, route of administration, or in other
cancer types. Such investigations are needed to know
whether this is a generalizable finding.
DC cancer vaccine trials have resulted in varied im-
munological and clinical responses [19]. It is becoming
increasingly clear that DCs may require adjuvants and
this is demonstrated by the recent breakthroughs using
CTLA4 and PD1 blockade [20,21]. While CD14magnetic selection generates a highly pure population of
precursor monocytes, the data presented here demon-
strate that purity may actually hinder potency. Since
there was no detectable difference in the cell surface
phenotype or in vitro function of Adherence and Se-
lected DC besides the presence of activated lymphocytes,
we propose that these lymphocytes provide a needed adju-
vant effect. Of note, the only DC tumor vaccine approved
by the FDA, Sipuleucel-T, is generated by isolating cells
with density gradient centrifugation and is therefore highly
unlikely to contain DCs exclusively. It is possible that the
activity of this agent is in part due to the presence of acti-
vated lymphocytes [22]. Future studies will focus on dis-
secting which signals from activated lymphocytes are
necessary and sufficient to optimize DC vaccines.
Conclusions
A surprising difference found in the immunogenicity of
DC cancer vaccines made by two different methods of
DC preparation prompted us to look into the underlying
causes. We found that the dose of DCs administered,
DC phenotype, and viability was similar in both vaccine
types given. In vitro DC function as assessed by allo-
MLR and proliferation assays were also similar. How-
ever, we show that DCs generated by the Adherence
method are accompanied by proliferating and activated
lymphocytes. We hypothesize that the presence of acti-
vated lymphocytes may contribute to the enhanced re-
sponses seen in patients given vaccine made using this
preparation method. This is an important finding, given
the variety of methods used in preparing DC vaccine
studies and the mixed post-vaccination responses seen.
As we evaluate DC vaccines in the future, it is impera-
tive that we consider methods of DC preparation and
how this may play a role in post-vaccination responses.
Further investigation is warranted with more patients
and with other variables, as this finding could have im-
portant ramifications for future DC vaccine preparation
strategies.
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